Literature DB >> 12803236

Mortality in 154 surgically treated patients with acromegaly--a 10-year follow-up survey.

Kazunori Arita1, Kaoru Kurisu, Atushi Tominaga, Kuniki Eguchi, Koji Iida, Tohru Uozumi, Fumiyoshi Kasagi.   

Abstract

To determine the effects of surgery and adjuvant therapy on the mortality rate of Japanese patients with acromegaly, 154 surgically treated patients were followed until death or December 2000. Mean follow-up period was 10.0 +/- 6.5 (SD) years. Postoperative GH levels, mean values of GH levels measured in the first postoperative month, were <2.5 ng/mL in 73 (47.4%), 2.5-5.0 ng/mL in 50 (32.5%), and >5.0 ng/mL in 31 patients (20.1%). Three of 123 patients with postoperative GH levels <5.0 ng/mL underwent a second transsphenoidal surgery (TSS), the other 120 received no further treatment. Additional treatments, including second TSS, medical treatment, and gamma-knife irradiation for residual tumor, were administered to 25 of 31 patients whose postoperative GH was >5.0 ng/mL. Among the total 154 patients surveyed, 11 (7.1%) died during the follow-up period. The standard mortality ratio (SMR) was 1.17, not different from age- and sex-matched controls. The SMR of the 72 patients with postoperative GH <2.5 ng/mL was better than that of the 51 patients whose postoperative GH was 2.5-5.0 ng/mL (1.09 vs. 1.64); however, the difference was not statistically significant. In conclusion, TSS and adequate adjuvant treatment decreased the excess mortality rate of acromegalics to nearly the same level as that of the general Japanese population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12803236     DOI: 10.1507/endocrj.50.163

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study.

Authors:  Lakshminarayanan Varadhan; Raoul C Reulen; Maureen Brown; Richard N Clayton
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

Review 2.  Excess mortality for patients with residual disease following resection of pituitary adenomas.

Authors:  Michael E Sughrue; Edward F Chang; Rodney A Gabriel; Manish K Aghi; Lewis S Blevins
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

3.  Transsphenoidal surgical treatment of pituitary adenomas in patients aged 80 years or older.

Authors:  Shunji Yunoue; Hiroshi Tokimura; Atsushi Tominaga; Shingo Fujio; Prasanna Karki; Satoshi Usui; Yasuyuki Kinoshita; Mika Habu; F M Moinuddin; Hirofumi Hirano; Kazunori Arita
Journal:  Neurosurg Rev       Date:  2013-11-15       Impact factor: 3.042

4.  Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed.

Authors:  Tirissa J Reid; Kalmon D Post; Jeffrey N Bruce; M Nabi Kanibir; Carlos M Reyes-Vidal; Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-16       Impact factor: 3.478

Review 5.  The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.

Authors:  Anne Klibanski; Shlomo Melmed; David R Clemmons; Annamaria Colao; Regina S Cunningham; Mark E Molitch; Aaron I Vinik; Daphne T Adelman; Karen J P Liebert
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

6.  Severe growth hormone deficiency is rare in surgically-cured acromegalics.

Authors:  Shingo Fujio; Hiroshi Tokimura; Hirofumi Hirano; Ryosuke Hanaya; Fumikatsu Kubo; Shunji Yunoue; Manoj Bohara; Yasuyuki Kinoshita; Atsushi Tominaga; Hiroshi Arimura; Kazunori Arita
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

7.  Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria.

Authors:  Masanori Yonenaga; Shingo Fujio; Mika Habu; Hiroshi Arimura; Takaaki Hiwatari; Shunichi Tanaka; Yasuyuki Kinoshita; Hiroshi Hosoyama; Hirofumi Hirano; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-02-23       Impact factor: 1.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.